← Back to Search
Immucillin H, A Powerful Transition-state Analog Inhibitor Of Purine Nucleoside Phosphorylase, Selectively Inhibits Human T Lymphocytes
G. Kicska, L. Long, H. Hörig, C. Fairchild, P. Tyler, R. Furneaux, V. Schramm, H. L. Kaufman
Published 2001 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Transition-state theory has led to the design of Immucillin-H (Imm-H), a picomolar inhibitor of purine nucleoside phosphorylase (PNP). In humans, PNP is the only route for degradation of deoxyguanosine, and genetic deficiency of this enzyme leads to profound T cell-mediated immunosuppression. This study reports the biological effects and mechanism of action of Imm-H on malignant T cell lines and on normal activated human peripheral T cells. Imm-H inhibits the growth of malignant T cell leukemia lines with the induction of apoptosis. Imm-H also inhibits activated normal human T cells after antigenic stimulation in vitro. However, Imm-H did not inhibit malignant B cells, colon cancer cell lines, or normal human nonstimulated T cells, demonstrating the selective activity of Imm-H. The effects on leukemia cells were mediated by the cellular phosphorylation of deoxyguanosine and the accumulation of dGTP, an inhibitor of ribonucleotide diphosphate reductase. Cells were protected from the toxic effects of Imm-H when deoxyguanosine was absent or when deoxycytidine was present. Guanosine incorporation into nucleic acids was selectively blocked by Imm-H with no effect on guanine, adenine, adenosine, or deoxycytidine incorporation. Imm-H may have clinical potential for treatment of human T cell leukemia and lymphoma and for other diseases characterized by abnormal activation of T lymphocytes. The design of Imm-H from an enzymatic transition-state analysis exemplifies a powerful approach for developing high-affinity enzyme inhibitors with pharmacologic activity.
This paper references
Regulation of purine metabolism by plasma membrane and cytoplasmic 5'-nucleotidases.
N. Edwards (1982)
Roles of Alternative Synthetic and Catabolic Purine Pathways in T Lymphocyte Differentiation a
A. Cohen (1985)
Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells.
G. Davison (2000)
Pre-steady-state transition-state analysis of the hydrolytic reaction catalyzed by purine nucleoside phosphorylase.
P. Kline (1995)
Cloning and expression of human deoxycytidine kinase cDNA.
E. Chottiner (1991)
Application of crystallographic and modeling methods in the design of purine nucleoside phosphorylase inhibitors.
S. Ealick (1991)
Isolation and characterization of purine-nucleoside phosphorylase-deficient T-lymphoma cells and secondary mutants with altered ribonucleotide reductase: genetic model for immunodeficiency disease.
B. Ullman (1979)
Methotrexate resistance in al L1210 cell line resulting from increased dihydrofolate reductase, decreased thymidylate synthetase activity, and normal membrane transport. Computer simulations based on network thermodynamics.
J. C. White (1981)
Transplantation 69, 1341–1347
G. M. Davison (2000)
Purine nucleoside phosphorylase. Catalytic mechanism and transition-state analysis of the arsenolysis reaction.
P. Kline (1993)
One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase.
R. W. Miles (1998)
Erythrocyte metabolism in purine nucleoside phosphorylase deficiency after enzyme replacement therapy by infusion of erythrocytes.
G. E. Staal (1980)
Purine nucleoside phosphorylase deficiency associated with selective cellular immunodeficiency.
J. Stoop (1977)
Protein properties of the subunits of ribonucleotide reductase and the specificity of the allosteric site(s).
J. Cory (1986)
Inhibitors of the enzyme purine nucleoside phosphorylase
P. Morris (1998)
In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
S. Bantia (1996)
Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine
H. Kawasaki (1993)
Control of immune pathology by regulatory T cells.
D. Mason (1998)
Synthesis of transition state analogue inhibitors for purine nucleoside phosphorylase and N-riboside hydrolases
G. B. Evans (2000)
Analog approaches to the structure of the transition state in enzyme reactions
R. Wolfenden (1972)
The Metabolic basis of inherited disease
Charles R.scriver (1989)
Common variable immunodeficiency and purine nucleotidase and nucleoside phosphorylase deficiency. A case report.
P. A. Ostergaard (1980)
The metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiency.
W. Osborne (1983)
Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells.
B. Mitchell (1978)
Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution.
S. Ealick (1990)
Enzymatic transition states and transition state analog design.
V. Schramm (1998)
This paper is referenced by
Analysis of the reaction coordinate of alpha-L-fucosidases: a combined structural and quantum mechanical approach.
Alicia Lammerts van Bueren (2010)
The Synthesis of N-Ribosyl Transferase Inhibitors Based on a Transition State Blueprint
G. B. Evans (2004)
Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk Analysis
Giuseppina La Sala (2017)
Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
R. Alonso (2009)
Celebrating the SSCI: the drug discovery pathway: challenges and pitfalls.
J. Bennett (2003)
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).
E. Olsen (2011)
47th Annual Meeting of the American Society of Hematology Atlanta, GA.
T-Cell Lymphoma (2006)
The transition state analog inhibitor of Purine Nucleoside Phosphorylase (PNP) Immucillin-H arrests bone loss in rat periodontal disease models.
C. Deves (2013)
Activation of guanine-β-D-arabinofuranoside and deoxyguanosine to triphosphates by a common pathway blocks T lymphoblasts at different checkpoints.
Luigi Leanza (2010)
Metabolic Interrelations within Guanine Deoxynucleotide Pools for Mitochondrial and Nuclear DNA Maintenance*
Luigi Leanza (2008)
Cordyceps Mushroom: A Potent Anticancer Nutraceutical
Md. Asaduzzaman Khan (2010)
Straightforward Microwave‐Assisted Synthesis of 5,8‐Disubstituted 5,6,8,9‐Tetrahydro‐4H,7H‐2,5,6a,8,9a‐pentaazaphenalene‐1,3‐diones
Daniel Garcia (2013)
In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia.
I. Homminga (2011)
Emerging Pharmacotherapies for Adult Patients with Acute Lymphoblastic Leukemia
L. Lee (2012)
Nucleoside analogs: molecular mechanisms signaling cell death
B. Ewald (2008)
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
K. Balakrishnan (2013)
C-Nucleosides To Be Revisited.
E. Clercq (2016)
PMP–diketopiperazine adducts form at the active site of a PLP dependent enzyme involved in formycin biosynthesis† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9cc06975e
Sisi Gao (2019)
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
M. Duvic (2013)
Iminosugars as therapeutic agents: recent advances and promising trends.
R. Nash (2011)
Les Iminosucres : applications thérapeutiques actuelles et futures
O. Martin (2007)
Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells.
K. Balakrishnan (2010)
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma
D. Maruyama (2018)
Synthesis of Ribo-Azanucleosides by Anodic Oxidation: Reactivity Control of Intermediate for Efficient Access to Pharmacophores.
K. Okamoto (2018)
The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase*
Elisa Franzolin (2015)
PNP diminishes guanosine glycosidic bond strength through restrictive ring pucker as a precursor to phosphorylation.
Christopher B. Barnett (2013)
Energetic Mapping of Transition State Analogue Interactions with Human and Plasmodium falciparum Purine Nucleoside Phosphorylases*♦
A. Lewandowicz (2005)
Treatment of Cutaneous T-cell Lymphomas
K. M. Cox (2010)
Chapter 2 – Antimetabolites
C. Avendaño (2008)
Glycosidase inhibition: assessing mimicry of the transition state
T. Gloster (2010)
Defective Nucleotide Catabolism Defines a Subset of Cancers Sensitive to Purine Nucleoside Phosphorylase Inhibition
Evan R. Abt (2019)
New Agents for the Treatment of Acute Lymphblastic Leukemia
V. Saha (2011)See more